{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:42:58Z","timestamp":1790160178596,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jtho.2016.05.020","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T20:05:32Z","timestamp":1465243532000},"page":"1615-1626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing"],"prefix":"10.1016","volume":"11","author":[{"given":"Marieke","family":"Hylebos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Van Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P","family":"van Meerbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Op de Beeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.05.020_bib1","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart","year":"2004"},{"key":"10.1016\/j.jtho.2016.05.020_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30227","article-title":"The pathogenesis of mesothelioma","volume":"29","author":"Carbone","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.020_bib4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1179\/oeh.2003.9.3.206","article-title":"Malignant mesothelioma in Australia, 1945-2002","volume":"9","author":"Leigh","year":"2003","journal-title":"Int J Occup Environ Health"},{"key":"10.1016\/j.jtho.2016.05.020_bib6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1289\/ehp.1002285","article-title":"The case for a global ban on asbestos","volume":"118","author":"LaDou","year":"2010","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jtho.2016.05.020_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2010.04.004","article-title":"Malignant pleural mesothelioma: the standard of care and challenges for future management","volume":"78","author":"van Meerbeeck","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtho.2016.05.020_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.semtcvs.2009.07.004","article-title":"Multimodality strategies in malignant pleural mesothelioma","volume":"21","author":"Weder","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2016.05.020_bib9","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib10","first-page":"319","article-title":"Mesothelioma treatment: are we on target? A review","volume":"6","author":"Hiddinga","year":"2015","journal-title":"J\u00a0Adv Res"},{"key":"10.1016\/j.jtho.2016.05.020_bib11","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.020_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/bjc.1989.326","article-title":"Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma","volume":"60","author":"Tiainen","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1997.91","article-title":"Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma","volume":"75","author":"Bjorkqvist","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/bjc.1998.42","article-title":"Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung","volume":"77","author":"Bjorkqvist","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib16","first-page":"450","article-title":"Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma","volume":"59","author":"Balsara","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.020_bib17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/path.1128","article-title":"Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases","volume":"197","author":"Krismann","year":"2002","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2016.05.020_bib18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","article-title":"Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32","volume":"98","author":"Taniguchi","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2016.05.020_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ijc.23949","article-title":"Genomic events associated with progression of pleural malignant mesothelioma","volume":"124","author":"Ivanov","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib20","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/onc.2009.455","article-title":"The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival","volume":"29","author":"Cheung","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2016.05.020_bib21","first-page":"0","article-title":"Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration","author":"Borczuk","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jtho.2016.05.020_bib22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2","article-title":"The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma","volume":"75","author":"Prins","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib23","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.020_bib24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations\u00a0and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2016.05.020_bib25","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1073\/pnas.0712399105","article-title":"Transcriptome sequencing of malignant pleural mesothelioma tumors","volume":"105","author":"Sugarbaker","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.05.020_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1471-2350-10-149","article-title":"Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel\u00a0transcriptome sequencing","volume":"10","author":"Dong","year":"2009","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jtho.2016.05.020_bib27","doi-asserted-by":"crossref","first-page":"e10612","DOI":"10.1371\/journal.pone.0010612","article-title":"Second generation sequencing of the mesothelioma tumor genome","volume":"5","author":"Bueno","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.jtho.2016.05.020_bib28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.020_bib29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00408-015-9814-7","article-title":"Driver gene and novel mutations in asbestos-exposed lung adenocarcinoma and malignant mesothelioma detected by exome sequencing","volume":"194","author":"M\u00e4ki-Nevala","year":"2015","journal-title":"Lung"},{"key":"10.1016\/j.jtho.2016.05.020_bib31","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.18632\/oncotarget.7032","article-title":"Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas","author":"Kang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2016.05.020_bib32","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2016.05.020_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/bj20021914","article-title":"Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases","volume":"373","author":"Qi","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.jtho.2016.05.020_bib34","doi-asserted-by":"crossref","first-page":"C966","DOI":"10.1152\/ajpcell.00571.2005","article-title":"DPP10 is an inactivation modulatory protein of Kv4.3 and Kv1.4","volume":"291","author":"Li","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jtho.2016.05.020_bib35","unstructured":"Lu SK, Anbunathan H, Popat S, et\u00a0al. Molecular landscape of malignant mesothelioma from whole exome sequencing [abstract]. Paper presented at 16th World Conference on Lung Cancer. September 6\u20139, 2015; Denver, CO."},{"key":"10.1016\/j.jtho.2016.05.020_bib36","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.020_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","article-title":"Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus","volume":"140","author":"Li","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2016.05.020_bib38","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Lopez-Lago","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jtho.2016.05.020_bib39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","article-title":"EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma","volume":"54","author":"Edwards","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2010.01.002","article-title":"Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma","volume":"70","author":"Gaafar","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib42","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/JTO.0b013e31829ceb6a","article-title":"Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior","volume":"8","author":"Goparaju","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib43","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1038\/onc.2013.239","article-title":"Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis","volume":"33","author":"Rodriguez-Paredes","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2016.05.020_bib44","doi-asserted-by":"crossref","first-page":"W77","DOI":"10.1093\/nar\/gkt439","article-title":"WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013","volume":"41","author":"Wang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtho.2016.05.020_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semcdb.2014.03.016","article-title":"The alternative splicing side of cancer","volume":"32","author":"Biamonti","year":"2014","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.jtho.2016.05.020_bib46","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/02841860601156157","article-title":"Expression microarray analysis reveals genes associated with in\u00a0vitro resistance to cisplatin in a cell line model","volume":"46","author":"Watson","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib47","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1089\/cbr.2012.1431","article-title":"Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis","volume":"28","author":"Lu","year":"2013","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.jtho.2016.05.020_bib48","first-page":"1351","article-title":"Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line","volume":"6","author":"Xu","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jtho.2016.05.020_bib49","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4161\/cc.7.7.5637","article-title":"Switching cyclin D-Cdk4 kinase activity on and off","volume":"7","author":"Blain","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jtho.2016.05.020_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","article-title":"Lessons from the cancer genome","volume":"153","author":"Garraway","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2016.05.020_bib51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3","article-title":"The p53 pathway","volume":"187","author":"Prives","year":"1999","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2016.05.020_bib52","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","article-title":"The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2","volume":"17","author":"Stott","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.jtho.2016.05.020_bib53","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/1078-0432.CCR-10-2345","article-title":"Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors","volume":"17","author":"Shapiro","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.020_bib54","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2014.06.008","article-title":"Randomized phase II trial of pemetrexed\/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma","volume":"85","author":"Krug","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib55","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2016.05.020_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/jcmm.12000","article-title":"PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT\/mTOR axis via SIRT1","volume":"17","author":"Pinton","year":"2013","journal-title":"J\u00a0Cell Molec Med"},{"key":"10.1016\/j.jtho.2016.05.020_bib57","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0092-8674(95)90214-7","article-title":"Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest","volume":"83","author":"Quelle","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2016.05.020_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrm1547","article-title":"Function and regulation of cullin-RING ubiquitin ligases","volume":"6","author":"Petroski","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jtho.2016.05.020_bib59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.020_bib60","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A\u00a0phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib61","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib62","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1074\/jbc.M108975200","article-title":"The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria","volume":"277","author":"Tsuruta","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtho.2016.05.020_bib63","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.jtho.2016.05.020_bib64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"Ou","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2016.05.020_bib65","doi-asserted-by":"crossref","first-page":"e18557","DOI":"10.1200\/jco.2013.31.15_suppl.e18557","article-title":"Combination efficacy\u00a0of mTOR and MEK inhibitor in malignant pleural\u00a0mesothelioma (MPM)","volume":"31","author":"Matsumoto","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib66","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12885-015-1363-1","article-title":"The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma","volume":"15","author":"Pignochino","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2016.05.020_bib67","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2016.05.020_bib68","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.020_bib69","first-page":"2968","article-title":"Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma","volume":"55","author":"Xiao","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.020_bib70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/AJCPT94JVWIHBKRD","article-title":"Diagnostic usefulness of p16\/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis","volume":"139","author":"Wu","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtho.2016.05.020_bib71","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2016.05.020_bib72","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic\u00a0BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib73","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.humpath.2015.06.024","article-title":"BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma","volume":"46","author":"McGregor","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2016.05.020_bib74","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JTO.0b013e31829e7ef9","article-title":"Clinical characteristics\u00a0of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations","volume":"8","author":"Zauderer","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.020_bib75","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J\u00a0Transl Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1556086416304956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1556086416304956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T19:18:35Z","timestamp":1600715915000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416304956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1556086416304956"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.05.020","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.jtho.2016.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}